Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × isatuximab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 50 Neoplasms 6 Recurrence 5 Neoplasms, Plasma Cell 4 Renal Insufficiency 3 Paraproteinemias 3 Lymphoma 3 Hematologic Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms by Histologic Type 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Hematologic Diseases 2 Blood Protein Disorders 2 Smoldering Multiple Myeloma 1 Purpura 1 Prostatic Neoplasms 1 Neoplasm, Residual 1 Nausea 1 Natural Killer/T-cell Lymphoma 1 Monoclonal Gammopathy of Undetermined Significance 1 Macroglossia 1 Lymphoproliferative Disorders 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Immunoproliferative Disorders 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 20 blinatumomab 16 fludarabine 13 Cytarabine 13 Azacitidine 11 venetoclax 9 fludarabine phosphate 9 Rituximab 7 Dexamethasone 7 Methotrexate 6 Lenalidomide 6 Daunorubicin 6 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Mercaptopurine 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Cladribine 3 Busulfan 3 Asparaginase 3 tisagenlecleucel 2 thymoglobulin 2 pembrolizumab 2 nilotinib 2 midostaurin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡